Arnaud et al. developed a method called Neoscreen, based on exposure of tumor-infiltrating lymphocytes (TILs) to CD40-activated (CD40-act) B cells that optimizing the sensitivity of antigen validation. This evidence concerns the gene CD40 and neoplasm.